Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.

Abstract

Earlier introduction of infliximab (IFX) in Crohn's disease (CD) may be associated with a sustained remission. Children on scheduled IFX therapy for predominant luminal CD after successful induction (drop in PCDAI by≥15) and a minimum of 2-year IFX follow-up were included. We compared outcomes of children treated with early (within 3months from diagnosis) versus later IFX (after failing conventional therapy≥3months) and identify clinical predictors of sustained primary response (SPR) in our cohort. SPR was defined as CS-free clinical remission without requiring IFX dose escalation and/or surgical excision and/or switch to second anti-TNFs due to LOR or allergic reaction. Sixty-four children received IFX therapy for CD during the study period. Forty-three children on scheduled IFX therapy for luminal CD met the inclusion criteria. During the median follow-up of 3.05years (IQR 2.6-3.5years), SPR was observed in 17/43 (40%). SPR was associated with shorter time from diagnosis to the initiation of IFX (5.4 vs. 18.7months, p=0.006). Binary logistic regression using multiple variables also confirmed that only early use of IFX is associated with SPR. Early step-up use of IFX in children with CD with inadequate clinical response to conventional therapies leads to sustained primary response over 2years.